Triple
T22690316
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | CDK4 |
E561032
|
entity |
| Predicate | inhibitedByDrug |
P149275
|
FINISHED |
| Object | trilaciclib |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: trilaciclib | Statement: [CDK4, inhibitedByDrug, trilaciclib]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: trilaciclib Context triple: [CDK4, inhibitedByDrug, trilaciclib]
-
A.
paclitaxel
Paclitaxel is a chemotherapy drug that stabilizes microtubules to inhibit cell division and is widely used to treat various cancers, including breast, ovarian, and lung cancers.
-
B.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
C.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
D.
Abraxane
Abraxane is a nanoparticle albumin-bound formulation of the chemotherapy drug paclitaxel used to treat various cancers, including breast, lung, and pancreatic cancer.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: trilaciclib Target entity description: Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor used to protect bone marrow from chemotherapy-induced damage in patients with certain cancers.
-
A.
paclitaxel
Paclitaxel is a chemotherapy drug that stabilizes microtubules to inhibit cell division and is widely used to treat various cancers, including breast, ovarian, and lung cancers.
-
B.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
C.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
D.
Abraxane
Abraxane is a nanoparticle albumin-bound formulation of the chemotherapy drug paclitaxel used to treat various cancers, including breast, lung, and pancreatic cancer.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2454d71b48190a1f80af9f82b6fcf |
completed | April 17, 2026, 2:35 p.m. |
| NER | Named-entity recognition | batch_69f1789a1fd08190bce5fa0babe695d3 |
completed | April 29, 2026, 3:18 a.m. |
Created at: April 17, 2026, 3:13 p.m.